Becton Dickinson and Company (BDX)vsAnbio Biotechnology Class A Ordinary Shares (NNNN)
BDX
Becton Dickinson and Company
$158.27
+1.51%
HEALTHCARE · Cap: $56.49B
NNNN
Anbio Biotechnology Class A Ordinary Shares
$23.76
+2.46%
HEALTHCARE · Cap: $1.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Becton Dickinson and Company generates 316712% more annual revenue ($21.92B vs $6.92M). NNNN leads profitability with a 37.2% profit margin vs 8.0%. BDX trades at a lower P/E of 25.5x. BDX earns a higher WallStSmart Score of 61/100 (C+).
BDX
Buy61
out of 100
Grade: C+
NNNN
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+36.9%
Fair Value
$286.42
Current Price
$158.27
$128.15 discount
Margin of Safety
-3894.1%
Fair Value
$0.68
Current Price
$23.76
$23.08 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Earnings expanding 28.6% YoY
Keeps 37 of every $100 in revenue as profit
Strong operational efficiency at 73.5%
Safe zone — low bankruptcy risk
Areas to Watch
Moderate valuation
1.6% revenue growth
ROE of 7.0% — below average capital efficiency
Distress zone — elevated risk
2.8% earnings growth
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Trading at 37.7x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : BDX
The strongest argument for BDX centers on Market Cap, Price/Book, EPS Growth. PEG of 1.16 suggests the stock is reasonably priced for its growth.
Bull Case : NNNN
The strongest argument for NNNN centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 37.2% and operating margin at 73.5%.
Bear Case : BDX
The primary concerns for BDX are P/E Ratio, Revenue Growth, Return on Equity.
Bear Case : NNNN
The primary concerns for NNNN are EPS Growth, Market Cap, P/E Ratio. A P/E of 386.5x leaves little room for execution misses.
Key Dynamics to Monitor
BDX profiles as a value stock while NNNN is a declining play — different risk/reward profiles.
BDX is growing revenue faster at 1.6% — sustainability is the question.
BDX generates stronger free cash flow (549M), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BDX scores higher overall (61/100 vs 37/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Becton Dickinson and Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
Visit Website →Anbio Biotechnology Class A Ordinary Shares
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. The company is headquartered in Frankfurt am Main, Germany.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?